Published in Vaccine Weekly, June 8th, 1998
The vaccine is made up of fusion cells (FC) created by combining the nuclei of carcinoma cells and dendritic cells. Dendritic cells (DC) are the body's chief antigen-presenting cell (APC) for generating cytotoxic T-lymphocyte (CTL) immune responses.
"A DC fusion cell vaccine can reverse unresponsiveness to a tumor-associated antigen and induce the rejection of established metastases," wrote Jianlin Gong of Harvard's Dana-Farber Cancer Institute, Boston, Massachusetts, and colleagues.
Gong et al. reported their findings in the Proceedings of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (1998-06-08)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.